SEZI Stock Overview
Senzime AB (publ), a medical device company, develops, manufactures, and markets patient monitoring systems to monitor patients in Europe and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Senzime AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.03 |
| 52 Week High | kr8.46 |
| 52 Week Low | kr2.61 |
| Beta | 0.53 |
| 1 Month Change | -5.34% |
| 3 Month Change | -24.25% |
| 1 Year Change | 15.08% |
| 3 Year Change | -73.78% |
| 5 Year Change | -4.89% |
| Change since IPO | -29.88% |
Recent News & Updates
Recent updates
Will Senzime (STO:SEZI) Spend Its Cash Wisely?
Feb 20
We Think Senzime (STO:SEZI) Can Afford To Drive Business Growth
Sep 01Companies Like Senzime (STO:SEZI) Are In A Position To Invest In Growth
May 18How Much Of Senzime AB (publ) (STO:SEZI) Do Insiders Own?
Mar 15Shareholders of Senzime (STO:SEZI) Must Be Delighted With Their 607% Total Return
Feb 16
We're Hopeful That Senzime (STO:SEZI) Will Use Its Cash Wisely
Jan 19Are Insiders Buying Senzime AB (publ) (STO:SEZI) Stock?
Dec 23What Kind Of Investors Own Most Of Senzime AB (publ) (STO:SEZI)?
Nov 26Shareholder Returns
| SEZI | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -4.4% | -0.7% | -1.7% |
| 1Y | 15.1% | -8.8% | 8.1% |
Return vs Industry: SEZI exceeded the Swedish Medical Equipment industry which returned -8.8% over the past year.
Return vs Market: SEZI exceeded the Swedish Market which returned 8.1% over the past year.
Price Volatility
| SEZI volatility | |
|---|---|
| SEZI Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: SEZI's share price has been volatile over the past 3 months.
Volatility Over Time: SEZI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 45 | Philip Siberg | senzime.com |
Senzime AB (publ), a medical device company, develops, manufactures, and markets patient monitoring systems to monitor patients in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor; TetraSens for measurement of muscle response to a stimulus; TetraSens Pediatric for decision support; TetraConnect, a data management portal that helps to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and ExSpiron 2Xi, a non-invasive respiratory volume monitor, as well as TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and OnZurf Probe, a sterile single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver.
Senzime AB (publ) Fundamentals Summary
| SEZI fundamental statistics | |
|---|---|
| Market cap | kr721.82m |
| Earnings (TTM) | -kr134.15m |
| Revenue (TTM) | kr35.75m |
20.2x
P/S Ratio-5.4x
P/E RatioIs SEZI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEZI income statement (TTM) | |
|---|---|
| Revenue | kr35.75m |
| Cost of Revenue | kr27.42m |
| Gross Profit | kr8.34m |
| Other Expenses | kr142.49m |
| Earnings | -kr134.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 23.32% |
| Net Profit Margin | -375.20% |
| Debt/Equity Ratio | 0% |
How did SEZI perform over the long term?
See historical performance and comparison